Table 1.
Pre-clinical studies of cannabinoids in cancer models that report original data from PubMed and EBSCO literature searches, categorized by study type and compound studied
| Cancer type | No. of original data | Study type |
Compound studied |
|||||
|---|---|---|---|---|---|---|---|---|
| In vivo | In vitro | Both in vivo and in vitro | THC alone | CBD alone | Multiple including THC or CBDa | Other cannabinoidb | ||
| Breast | 19 | 4 | 9 | 6 | 4 | 6 | 1 | 8 |
| CNS | 20 | 2 | 12 | 6 | 2 | 4 | 5 | 9 |
| Colorectal | 10 | 0 | 5 | 5 | 0 | 2 | 2 | 6 |
| Gynecological | 4 | 0 | 3 | 1 | 0 | 3 | 1 | 0 |
| Leukemia | 6 | 0 | 4 | 2 | 1 | 3 | 1 | 1 |
| Lung | 9 | 1 | 3 | 5 | 1 | 2 | 2 | 4 |
| Melanoma | 4 | 3 | 1 | 0 | 1 | 0 | 2 | 1 |
| Prostate | 6 | 1 | 3 | 2 | 0 | 0 | 1 | 5 |
| Multiple | 8 | 0 | 5 | 3 | 1 | 1 | 1 | 5 |
| Otherc | 21 | 1 | 14 | 6 | 2 | 1 | 3 | 15 |
| Total | 107 | 12 | 59 | 36 | 12 | 22 | 19 | 54 |
Articles that studied THC and CBD, in combination or separately, THC with other cannabinoid (non-CBD or –THC phytocannabinoid or synthetic), in combination or separately, or CBD with other cannabinoid (non-CBD or –THC phytocannabinoid or synthetic), in combination or separately.
Articles that studied non-CBD or –THC phytocannabinoid or synthetic cannabinoids.
Other cancers include Bile duct, Gastric, Head and Neck, Kidney, Liver, Lymphoma, Non-melanoma, Pancreas, Testicular, Thyroid, and Urological.
CBD, cannabidiol; CNS, central nervous system; THC, delta9-tetrahydrocannabinol.